Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: A nationwide cohort study

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 4, 2015, Pages 495-504

  Gorst Rasmussen, A ^a,b   Skjoth F ^a,b   Larsen, T B ^a,b   Rasmussen, L H ^b   Lip, G Y H ^b,c   Lane, D A ^b,c  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Anticoagulants; Atrial fibrillation; Dabigatran; Medication adherence; Pharmacoepidemiology

Indexed keywords

DABIGATRAN; HEPARIN; RIVAROXABAN; WARFARIN; ANTITHROMBIN;

ADULT; AGED; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; DISEASE REGISTRY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEALTH CARE SYSTEM; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MORBIDITY; PRESCRIPTION; PRIORITY JOURNAL; ATRIAL FIBRILLATION; ATTITUDE TO HEALTH; CHEMICALLY INDUCED; DENMARK; ORAL DRUG ADMINISTRATION; REGISTER; RISK FACTOR; STROKE; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTITHROMBINS; ATRIAL FIBRILLATION; COHORT STUDIES; COMORBIDITY; DABIGATRAN; DENMARK; DRUG PRESCRIPTIONS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEMORRHAGE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; REGISTRIES; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84926120551     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12845     Document Type: Article

References (33)

1. Kneeland PP, Fang MC. Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence 2010; 4: 51-60.
2. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-429.
3. Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation - developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14: 1385-413.
4. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GYH, Morais J, Rasmussen LH, Siegbahn A, Verheugt FWA, Weitz JI. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-107.
5. Rodriguez RA, Carrier M, Wells PS. Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation? J Thromb Haemost 2013; 11: 390-4.
6. Husted S, De Caterina R, Andreotti F, Arnesen H, Bachmann F, Huber K, Jespersen J, Kristensen SD, Lip GYH, Morais J, Rasmussen LH, Siegbahn A, Storey RF, Weitz JI; Esc Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease OBOT. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel. Thromb Haemost 2014; 111: 781-2.
7. Schulman S. New oral anticoagulant agents - general features and outcomes in subsets of patients. Thromb Haemost 2014; 111: 575-82.
8. Ten Cate H. Monitoring new oral anticoagulants, managing thrombosis, or both? Thromb Haemost 2012; 107: 803-5.
9. Alberts MJ, Eikelboom JW, Hankey GJ. Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. Lancet Neurol 2012; 11: 1066-81.
10. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-97.
11. Sabaté E, ed. Adherence to Long-Term Therapies: Evidence for Action. Geneva: World Health Organisation, 2003: 1-194.
12. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713-9.
13. Srivastava K, Arora A, Kataria A, Cappelleri JC, Sadosky A, Peterson AM. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence 2013; 7: 419-34.
14. Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y, Walker D, Sander S, Miyasato G, Matchar D, Sanchez H. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 2013; 6: 567-74.
15. Schulman S, Shortt B, Robinson M, Eikelboom JW. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost 2013; 11: 1295-9.
16. Sanz G, Fuster V. Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population. Nat Clin Pract Cardiovasc Med 2009; 6: 101-10.
17. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 44-7.
18. Yu AP, Yu YF, Nichol MB. Estimating the effect of medication adherence on health outcomes among patients with type 2 diabetes-an application of marginal structural models. Value Health 2010; 13: 1038-45.
19. Kildemoes HW, Sørensen HT, Hallas J. The Danish national prescription registry. Scand J Public Health 2011; 39: 38-41.
20. Lynge E, Sandegaard JL, Rebolj M. The Danish national patient register. Scand J Public Health 2011; 39: 30-3.
21. Pedersen CB. The Danish civil registration system. Scand J Public Health 2011; 39: 22-5.
22. Larsen TB, Gorst-Rasmussen A, Rasmussen LH, Skjøth F, Rosenzweig M, Lip GYH. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med 2014; 127: 650-6.e5.
23. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006; 15: 565-74; discussion 575-7.
24. Tsai K, Erickson SC, Yang J, Harada AS, Solow BK, Lew HC. Adherence, persistence, and switching patterns of dabigatran etexilate. Am J Manag Care 2013; 19: e325-32.
25. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-52.
26. Schulman S. Advantages and limitations of the new anticoagulants. J Intern Med 2014; 275: 1-11.
27. January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC, Cigarroa JE, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: e1-76.
28. Clarkesmith DE, Pattison HM, Lip GYH, Lane DA. Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS One 2013; 8: e74037.
29. Pamboukian SV, Nisar I, Patel S, Gu L, McLeod M, Costanzo MR, Heroux A. Factors associated with non-adherence to therapy with warfarin in a population of chronic heart failure patients. Clin Cardiol 2008; 31: 30.
30. Avgil Tsadok M, Jackevicius CA, Rahme E, Humphries KH, Behlouli H, Pilote L. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. J Am Med Assoc 2012; 307: 1952-8.
31. Dagres N, Nieuwlaat R, Vardas PE, Andresen D, Lévy S, Cobbe S, Kremastinos DT, Breithardt G, Cokkinos DV, Crijns HJ. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol 2007; 49: 572-7.
32. Rix TA, Riahi S, Overvad K, Lundbye-Christiensen S, Schmidt EB, Joensen AM. Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry. Scand Cardiovasc J 2012; 46: 149-53.
33. Avorn J. The relative cost-effectiveness of anticoagulants: obvious, except for the cost and the effectiveness. Circulation 2011; 123: 2519-21.